Navigation Links
Synthetic Biology: funders move to address social and ethical challenges
Date:6/8/2008

The report of an independent review of social and ethical challenges associated with research into, and the application of, synthetic biology, is published today (9 June). The report, commissioned by the Biotechnology and Biological Sciences Research Council's (BBSRC) Bioscience for Society Strategy Panel, is part of its programme to ensure that BBSRC adequately addresses issues raised by this rapidly emerging area of science and technology. Embargoed copies of the report are available upon request (see contact details below).

Synthetic biology seeks to apply the principles of engineering to biological systems and processes. Scientists believe that it may lead to new applications, such as new energy production systems, medical therapies, biological computers and innovative ways to clean up hazardous waste. In common with other modern technologies, it is potentially controversial because it raises issues of ownership, misuse, unintended consequences, and accidental release.

The report, 'Synthetic Biology: social and ethical challenges', has been written by Andrew Balmer and Paul Martin of the Institute for Science and Society, University of Nottingham, a leading research centre working on the impact of new technology. It reviews what synthetic biology is, where it has come from, and where it is going, as well as making recommendations to research funders and the scientific community about how social and ethical issues should be addressed. These include:

  • The need for scientists to engage with the public early in the development of synthetic biology to ensure that research does not get ahead of public attitudes.
  • Synthetic biology must not be over-hyped by its supporters and critics should not exaggerate the risks it poses.
  • Reviewing current regulations and guidelines to ensure that an appropriate governance framework is in place before most synthetic biology applications are introduced.

BBSRC, with advice from its Bioscience for Society Strategy Panel, is considering the recommendations of the report and will use its conclusions to inform its future policy in this area.

"Synthetic biology is in the early stages of development in the UK, and it is an appropriate time to address issues of public interest and concern," said Professor Nigel Brown, BBSRC Director of Science and Technology, "BBSRC already requires its grantholders to address ethical and other social issues, but this report will help us to focus on those concerns associated with synthetic biology."

BBSRC is already working with its sister Research Councils on ethical and regulatory issues that might arise from synthetic biology research. BBSRC is working closely with the Engineering and Physical Sciences Research Council and the Royal Society on how to take forward public dialogue and engagement on the science of synthetic biology, and with the Economic and Social Research Council and the Arts and Humanities Research Council on wider societal issues.


'/>"/>
Contact: Nancy Mendoza
press.office@bbsrc.ac.uk
01-793-413-355
Biotechnology and Biological Sciences Research Council
Source:Eurekalert

Related biology news :

1. Chloroplast f and m Thioredoxins Discovered in Nonphotosynthetic Tissues
2. Synthetic compound promotes death of lung-cancer cells, tumors
3. Experts from Stevens, Merck, publish joint paper, Biosynthetic Studies of Platensimycin
4. Researchers decode genetics of rare photosynthetic bacteria
5. Researchers decode genetics of rare photosynthetic bacterium
6. Synthetic molecules may be less expensive alternative to therapeutic antibodies, researchers find
7. Berkeley researchers identify photosynthetic dimmer switch
8. Oregano oil works as well as synthetic insecticides to tackle common beetle pest
9. New projects to raise UK profile in synthetic biology
10. Clemson physicist addresses international forum on thermoelectric energy
11. UC-Riverside partners with Chinese university to address Chinas environmental problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... AUSTIN, Texas, March 29, 2017  Vermillion, Inc. ... gynecologic disease, reported on its results for the ... 2016. "2016 marked a pivotal year ... ACOG guideline inclusion, international distribution agreements, major reimbursement ... in network payer agreements. In addition we cleared ...
(Date:3/29/2017)... - Last year,s petition to the White House signed by ... to generate awareness on the importance of new organic medicines and ... market place. ... Earlier this month Health Advance (OTC PINK: HADV ... products, announced its endeavors on this generally recognized as safe ...
(Date:3/29/2017)... ... March 29, 2017 , ... (March ... International Mexico has been approved as an active member of the Mexican ... protection among distributers and consumers in relationship marketing. This professional organization fosters loyal ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
Breaking Biology Technology: